Omega-3 fatty acids and oral and systemic inflammation: A secondary analysis of a randomized trial in patients with coronary artery disease.

Denna sekundäranalys använde en randomiserad studie med 240 patienter med stabil kranskärlssjukdom som behandlades med statiner. Deltagarna fick 3,36 g/dag EPA plus DHA eller inget tillskott i 30 månader. Gingival crevicular fluid was available from the maxillary left and right quadrants in 199 participants, allowing oral as well as systemic inflammatory markers to be compared. EPA and DHA were associated with lower macrophage inflammatory protein-1β in the left gingival quadrant (p=0.038) and a lower neutrophil-to-lymphocyte ratio in blood (p=0.021). The abstract reports no significant oral marker effect in the right quadrant. Its authors proposed that handedness and toothbrushing behaviour might explain the localized left-side result, rather than a uniform oral effect. These outcomes are inflammatory markers, not periodontal disease progression, cardiovascular events, or survival. The study concerns people with established coronary artery disease on statins, so it is not direct evidence for healthy adults. The 30-month duration and original sample size are useful, but this was a secondary analysis with a site-specific finding that needs replication.

EPA and DHA supplementation lowered oral and systemic inflammation, with the site-specific oral difference requiring further investigation.